Skeletal events of Anastrozole versus Tamoxifen on bone mineral density and bone biomarker osteocalcin in postmenopausal women with early breast cancer
| Autor: | Karima M. Maher, Menha Swellam, Lobna R. Ezz Elarab, Manal M. Abdel Wahab |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Bone mineral
Oncology medicine.medical_specialty biology medicine.drug_class business.industry Anastrozole medicine.disease Breast cancer Endocrinology Estrogen Internal medicine medicine biology.protein Osteocalcin Biomarker (medicine) Aromatase skin and connective tissue diseases business Tamoxifen medicine.drug |
| Zdroj: | The Chinese-German Journal of Clinical Oncology. 9:574-578 |
| ISSN: | 1613-9089 1610-1979 |
| DOI: | 10.1007/s10330-010-0676-4 |
| Popis: | Objective Postmenopausal women with breast cancer are at increased risk of bone loss because of age related estrogen deficiency face which accelerated with the use of aromatase inhibitors (AIs). We aimed to study the effect on bone mineral density (BMD) and bone formation biomarker osteocalcin level in postmenopausal breast cancer patients, for the first three years of adjuvant hormonal treatment of both groups Tamoxifen versus Anastrozol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink